Annunziata Raimondo

Salerno, 84084, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Cutaneous Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Cohort Study of Clinical Spectrum and Treatment Patterns.

Cutaneous Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Cohort Study of Clinical Spectrum and Treatment Patterns.

Journal: Life (Basel, Switzerland)

Published: July 08, 2026

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Baricitinib versus ritlecitinib for severe alopecia areata: A 24-week real-world study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: April 11, 2026

Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast.

Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast.

Journal: Dermatology (Basel, Switzerland)

Published: March 04, 2026

Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study.

Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study.

Journal: American journal of clinical dermatology

Published: November 05, 2025

Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.

Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.

Journal: Clinical and experimental dermatology

Published: October 21, 2025

Drug Utilization and Medication Adherence: A Data-Driven Analysis of Drugs with Different Routes of Administration Applied in Atopic Dermatitis.

Drug Utilization and Medication Adherence: A Data-Driven Analysis of Drugs with Different Routes of Administration Applied in Atopic Dermatitis.

Journal: Pharmaceutics

Published: July 28, 2025

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.

Journal: Psoriasis (Auckland, N.Z.)

Published: April 08, 2025

Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results.

Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: February 28, 2025

Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study.

Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study.

Journal: Dermatology and therapy

Published: February 24, 2025

A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study.

A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: the EARLY study.

Journal: Clinical and experimental dermatology

Published: February 19, 2025

PDE4 Inhibition Reduced Osteoclast Differentiation in Psoriatic Patients.

PDE4 Inhibition Reduced Osteoclast Differentiation in Psoriatic Patients.

Journal: Life (Basel, Switzerland)

Published: February 19, 2025

Apremilast, Methotrexate and NB-UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison.

Apremilast, Methotrexate and NB-UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison.

Journal: Photodermatology, photoimmunology & photomedicine

Published: January 10, 2025

Showing 1-12 of 60

Last Updated: 09/26/2026